Intravaginal gels as drug delivery systems

Journal of Women's Health

Volumn 13, Issue 7, 2004, Pages 834-844

  Justin Temu, Mary ^a   Damain, Festo ^b   Kinget, Renaat ^b   Van Den Mooter, Guy ^b  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; CARBOMER; CARBOPOL 934; CARBOPOL 940; CARBOXYMETHYLCELLULOSE; CARRAGEENAN; CHLORHEXIDINE GLUCONATE; DECANOIC ACID; FLUOROURACIL; GELATIN; GELLING AGENT; HYALURONIC ACID; HYDROXYETHYLCELLULOSE; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; HYPOL; LACTIC ACID; MACROGOL; METHYLCELLULOSE; MISOPROSTOL; MONOACYLGLYCEROL; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PEPTIDE; POLYACRYLIC ACID; POLYCARBOPHIL; POLYSACCHARIDE; POVIDONE IODINE; PROGESTERONE; PROSTAGLANDIN E2; PROTEIN; UNINDEXED DRUG; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; FEMALE; FIRST PASS EFFECT; GEL; HUMAN; LIVER METABOLISM; MOLECULAR WEIGHT; MUCUS; PRIORITY JOURNAL; VAGINA; VAGINA MUCOSA; VASCULARIZATION;

ADMINISTRATION, INTRAVAGINAL; ANTI-INFECTIVE AGENTS, LOCAL; DRUG DELIVERY SYSTEMS; FEMALE; GELS; HUMANS;

EID: 5644283590     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2004.13.834     Document Type: Article

References (68)

1. Ansel HC, Popovich NG, Allen LV. Pharmaceutical dosage forms and drug delivery, 6th ed. Malvern, PA: Williams & Wilkins, 1985:424.
2. Jain SK, Singh R, Sahu B. Development of a liposome-based contraceptive system for intravaginal administration of progesterone. Drug Dev Ind Pharm 1997;23:827.
3. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm 1997;23:489.
4. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vagina PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003;17:321.
5. Van Damme L, Niruthisard S, Atisook R, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998;12:433.
6. Balzarini J, Naesens L, Verbeken E, et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998;12:1129.
7. Neyts J, Kristmundsdottir T, De Clercq E, Thormar H. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: Impact on the search for vaginal microbicides. J Med Virol 2000;61:107.
8. D'Cruz OJ, Waurzyniak B, Yiv SH, Uckun FM. Evaluation of subchronic (13-week) and reproductive toxicity potential of intravaginal gel-microemulsion formulation of a dual-function phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-05) in B6C3F1 mice. J Appl Toxicol 2000;20:319.
9. Deshpande AA, Rhodes CT, Danish M. Intravaginal drug delivery. Drug Dev Ind Pharm 1992;18:1225.
10. Pimlott SJ, Addy M. Evaluation of a method to study the uptake of prednisolone sodium phosphate from different oral mucosal sites. Oral Surg Oral Med Oral Pathol 1985;60:35.
11. Richardson JL, Armstrong TI. Vaginal delivery of calcitonin by hyaluronic acid formulations. In: Mathiowitz E, Chickering DE III, Lehr C-M, eds. Bioadhesive drug delivery systems: Fundamentals, novel approaches, and development. New York and Basel: Marcel Dekker Inc., 1999:563.
12. Hwang S, Owada E, Suhardja LHO, Flynn GL, Higuchi WI. Systems approach to vaginal delivery of drug. 4. Methodology for determination of membrane surface pH. J Pharm Sci 1977;66:778.
13. Levine H, Watson N. Comparison of the pharmacokinetics of Crinone® 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril 2000;73:516.
14. Richardson JL, Illum L. Penetration enhancement for polypeptides through epithelia. D. Routes of delivery-case studies. 8. The vaginal route of peptide and protein drug delivery. Adv Drug Deliv Rev 1992; 8:341.
15. Bulletti C, deZiegler D, Flamigni C, et al. Targeted drug delivery in gynaecology: The first uterine pass effect. Hum Reprod 1997;12:1073.
16. Knuth K, Amiji M, Robinson JR. Hydrogel delivery systems for vaginal and oral applications - Formulation and biological considerations. Adv Drug Deliv Rev 1993;11:137.
17. Stafford MK, Ward H, Flanagan A, et al. Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects. J Acq Immun Defic Syndr 1998;17:327.
18. Lee VHL. Enzymatic barriers to peptide and protein-absorption. CRC Crit Rev Ther Drug Carrier Syst 1988;5:69.
19. Hwang S, Owada E, Yotsuyanagi T, et al. Systems approach to vaginal delivery of drugs. II. In situ vaginal absorption of unbranched aliphatic alcohols. J Pharm. Sci 1976;65:1574.
20. Owada E, Behl CR, Hwang S, et al. Vaginal drug absorption in rhesus monkeys. I. Development of methodology. J Pharm Sci 1977;66:216.
21. Sanders JM, Matthews HB. Vaginal absorption of polyvinyl alcohol in Fischer 344 rats. Hum Exp Toxicol 1990;9:71.
22. Pena LE. Gel dosage forms: Theory, formulation and processing in topical drug delivery formulation. In: Oborne DW, Amann AH, eds. Drug and the pharmaceutical sciences. New York and Basel: Marcel Dekker, Inc., 1990:381.
23. Guyot M, Fawaz F. Present and future choices of vaginal drug dosage forms. I. Classical forms. J Pharm Belg 1993;48:393.
24. Luessaen HL, Verhoef JC, de Boer AG, et al. Multifunctional polymers for the peroral delivery of peptides drugs. In: Mathiowitz E, Chickering DE III, Lehr C-M, eds. Bioadhesive drug delivery systems: Fundamentals, novel approaches, and development. New York and Basel: Marcel Dekker Inc., 1999:299.
25. Guo J-H, Cremer K. Development of bioadhesive buccal patches. In: Mathiowitz E, Chickering DE III, Lehr C-M, eds. Bioadhesive drug delivery systems: Fundamentals, novel approaches, and development. New York and Basel: Marcel Dekker Inc., 1999:541.
26. Ugwoke MI. Development and evaluation of controlled released nasal drug delivery systems of apomorphine. Acta Biomed Lovaniensia 1999;206:43.
27. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000;50:27.
28. Gayot A. Bioadhesive polymers. J Pharm Belg 1985; 40:332.
29. Chickering DE III, Mathiowitz E. Definitions, mechanisms, and theories of bioadhesion. In: Mathiowitz E, Chickering DE III, Lehr C-M, eds. Bioadhesive drug delivery systems: Fundamentals, novel approaches, and development. New York and Basel: Marcel Dekker Inc., 1999:563.
30. Peppas NA, Sahlin JJ. Hydrogels as mucoadhesives materials: A review. Biomaterials 1996;17:1553.
31. Junginger HE. Mucoadhesive hydrogels. Pharm Ind 1991;53:1056.
32. Brannon-Peppas L. Novel vaginal drug release applications. Adv Drug Deliv Rev 1993;11:169.
33. Malolepsza-Jarmolowska K, Kubis AA. Studies on gynaecological hydrophilic lactic acid preparations. Part 3: Effects of chitosan on the properties of methylcellulose gels. Pharmazie 2000;55:610.
34. 2 pessary for cervical ripening and initiation of labor at term. Obstet Gynecol 1992;79:374.
35. 2 for cervical ripening and labor induction: The appropriate route and dose. Acta Obstet Gynecol Scand 1996;75:135.
36. Coury AJ, Ahatan PT, Jevne AH, Perrault JJ, Kallole MJ. Recent development in hydrophilic polymers. Med Diagn Ind 1987;6:28.
37. Broumas AC, Basara LA. Potential patient preference for 3-day treatment of bacterial vaginosis: Responses to new suppository form of clindamycin. Adv Ther 2000;17:159.
38. Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect 2000; 32:184.
39. Origoni M, Garsia S, Sideri M, Pifarotti G, Nicora M. Efficacy of topical oxatomide in women with pruritus vulvae. Drugs Exp Clin Res 1990;16:591.
40. Schneider KT, Luftner D, Rath W. Efficacy and safety of a 2-tier prostaglandin labor induction schedule. J Perinat Med 1994;22:399.
41. Gagne N, Cormier H, Omar RF, et al. Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9. Sex Transm Dis 1999;26:177.
42. Syed TA, Ahmadpour OA. Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: A placebo-controlled, double-blind study. Int J STD AIDS 1998;9:769.
43. Elias CJ, Coggins C, Alvarez F, et al. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception 1997;56:387.
44. Holst E, Brandberg A. Treatment of bacterial vaginosis in pregnancy with a lactate gel. Scand J Infect Dis 1990;22:625.
45. Patton DL, Sweeney YTC, McKay TL, et al. 0.25% Chlorhexidine gluconate-gel. A protective topical microbicide. Sex Transm Dis 1998;25:421.
46. 2 vaginal gel use in practice. J Clin Pharm Ther 1999;24:303.
47. 2 vaginal gel an alternative? Geburtsh Frauenheilk 1996;56:536.
48. Warren MP, Biller BMK, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: Effects of cyclic administration of progesterone from the sustained-release aginal gel Crinone® (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol 1999;180:42.
49. Damario MA, Goudas VT, Sesson DR, Hammitt DG, Dumesic DA. Crinone® 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer. Fertil Steril 1999;72:830.
50. Syed TA, Qureshi ZA, Ahmad SA, Ali SM. Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: A placebo-controlled double-blind study. Int J STD AIDS 2000;1:371.
51. 2 for cervical ripening and induction of labour: A comparison of gel and tablets. S Afr Med J 1980;58:516.
52. Amaral E, Faundes A, Zaneveld L, Waller D, Garg S. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception 1999;60:361.
53. 2 as an intracervical gel, with oxytocin immediately, or as a sustained-release vaginal insert. Am J Obstet Gynecol 1998; 179:1204.
54. Carlan SJ, Bouldin S, O'Brien WF. Extemporaneous preparation of Misoprostol® gel for cervical ripening: A randomized trial. Obstet Gynecol 1997;90:911.
55. Eason EL, Sampalis JS, Hemmings R, Joseph L. Povidone-iodine gel vaginal antisepsis for abdominal hysterectomy. Am J Obstet Gynecol 1997;176:1011.
56. Peppas NA, Keys KB, Torres-Lugo M, Lowman AM. Poly(ethylene glycol)-containing hydrogels in drug delivery. J Control Release 1999;62:81.
57. Sjöberg H, Persson S, Caram-Lelham N. How interactions between drugs and agarose-carrageenan hydrogels influence the simultaneous transport of drugs. J Control Release 1999;59:391.
58. Coggins C, Elias CJ, Atisook R, et al. Women's preferences regarding the formulation of over-the-counter vaginal spermicides. AIDS 1998;12:1389.
59. Lee CH, Chien YW. Development and evaluation of a mucoadhesive drug delivery system for dual-controlled delivery of nonoxynol-9. J Control Release 1996;39:93.
60. Owen DH, Dunmire EN, Planys AM, Katz DF. Factors influencing nonoxynol-9 permeation and bioactivity in cervical mucus. J Control Release 1999;60:23.
61. Pschera H, Hjerpe A, Carlstrom K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17-beta and progesterone in postmenopausal women. Gynecol Obstet Invest 1989;27:204.
62. Wilson PD. A comparison of four methods of ripening the unfavourable cervix. Br J Obstet Gynaecol 1978;85:941.
63. Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis - A comparison of vaginal gel vs. oral therapy. J Reprod Med 2000;45:889.
64. 2 intravaginal gel versus low dose oxytocin for cervical ripening before induction of labor. Am J Obstet Gynecol 1996;174:1910.
65. 2 gel. Aust NZ J Obstet Gynaecol 1992;32:25.
66. Kleinstein J, Schlegelmilch R, Mazur D, et al. Pharmacokinetic comparison of progesterone capsules with a progesterone gel after vaginal administration. Arzneimittelforschung 2002;52:615.
67. 2: A comparison between intracervical gel and vaginal pessary. J Matern Fetal Neonatal Med 2003;14:158.
68. 2 intracervical gel (Prepidil®), with immediate oxytocin versus vaginal insert (Cervidil®) for induction of labor. Am J Obstet Gynecol 1998; 179:1175.